HK1203073A1 - Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same - Google Patents

Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

Info

Publication number
HK1203073A1
HK1203073A1 HK15103588.5A HK15103588A HK1203073A1 HK 1203073 A1 HK1203073 A1 HK 1203073A1 HK 15103588 A HK15103588 A HK 15103588A HK 1203073 A1 HK1203073 A1 HK 1203073A1
Authority
HK
Hong Kong
Prior art keywords
dihydrate
salt
producing
same
benzothiophene compound
Prior art date
Application number
HK15103588.5A
Other languages
English (en)
Chinese (zh)
Inventor
Hiroshi Yamashita
Tetsuya Sato
Takuya Minowa
Yusuke Hoshika
Hidekazu Toyofuku
Tatsuya Yamaguchi
Masahiro Sota
Shuuji Kawano
Takayuki Nakamura
Ryohei Eto
Takuma Ikebuchi
Kei Moriyama
Nobuaki Ito
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1203073(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of HK1203073A1 publication Critical patent/HK1203073A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
HK15103588.5A 2012-04-23 2015-04-13 Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same HK1203073A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636920P 2012-04-23 2012-04-23
US201361791378P 2013-03-15 2013-03-15
PCT/JP2013/062681 WO2013162046A1 (en) 2012-04-23 2013-04-23 Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

Publications (1)

Publication Number Publication Date
HK1203073A1 true HK1203073A1 (en) 2015-10-16

Family

ID=48428584

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103588.5A HK1203073A1 (en) 2012-04-23 2015-04-13 Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

Country Status (37)

Country Link
US (5) US9499525B2 (ko)
EP (1) EP2841431B2 (ko)
JP (1) JP5952917B2 (ko)
KR (1) KR102160395B1 (ko)
CN (1) CN104254530B (ko)
AR (1) AR090774A1 (ko)
AU (1) AU2013253372B2 (ko)
BR (1) BR112014026424B1 (ko)
CA (1) CA2870000C (ko)
CO (1) CO7111315A2 (ko)
CY (1) CY1119103T1 (ko)
DK (1) DK2841431T4 (ko)
EA (1) EA026541B1 (ko)
ES (1) ES2617881T5 (ko)
FI (1) FI2841431T4 (ko)
HK (1) HK1203073A1 (ko)
HR (1) HRP20170242T4 (ko)
HU (1) HUE031997T2 (ko)
IL (1) IL235044B (ko)
IN (1) IN2014DN08867A (ko)
JO (1) JO3325B1 (ko)
LT (1) LT2841431T (ko)
ME (1) ME02619B (ko)
MX (1) MX361723B (ko)
MY (1) MY170220A (ko)
NZ (1) NZ630260A (ko)
PH (1) PH12014502324A1 (ko)
PL (1) PL2841431T5 (ko)
PT (1) PT2841431T (ko)
RS (1) RS55742B2 (ko)
SG (1) SG11201406790VA (ko)
SI (1) SI2841431T2 (ko)
SM (1) SMT201700130B (ko)
TW (1) TWI562991B (ko)
UA (1) UA117456C2 (ko)
WO (1) WO2013162046A1 (ko)
ZA (1) ZA201407477B (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
AR090775A1 (es) 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20210047A1 (ar) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
WO2015163486A1 (en) 2014-04-22 2015-10-29 Otsuka Pharmaceutical Co., Ltd. Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
CN104447723A (zh) * 2014-11-28 2015-03-25 瑞阳制药有限公司 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法
CN104829603A (zh) * 2015-05-19 2015-08-12 杭州新博思生物医药有限公司 A晶型依匹唑派盐酸盐及其制备方法
CN106883223B (zh) * 2015-12-16 2021-11-23 北京福元医药股份有限公司 一种Brexpiprazole盐酸盐的纯化方法
WO2017106641A1 (en) 2015-12-17 2017-06-22 Assia Chemical Industries Ltd. Solid state forms of brexpiprazole
WO2017115287A1 (en) 2015-12-28 2017-07-06 Honour (R&D) Process for the preparation of quinoline-2(1h)-one derivatives
JP2019059672A (ja) * 2015-12-28 2019-04-18 大日本住友製薬株式会社 治療抵抗性うつ病等の治療薬
US10501450B2 (en) 2016-02-01 2019-12-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations
US20170320862A1 (en) 2016-05-03 2017-11-09 Cadila Healthcare Limited Process for the preparation of brexpiprazole and intermediates thereof
CN107365305A (zh) * 2016-05-12 2017-11-21 上海奥博生物医药技术有限公司 一种依匹哌唑新晶型及其制备方法
WO2017208251A1 (en) * 2016-05-31 2017-12-07 Cipla Limited A new stable polymorph of brexpiprazole and process for preparation thereof
CN106188023A (zh) * 2016-07-04 2016-12-07 山东川成医药股份有限公司 一种依匹唑派的精制方法
PL233778B1 (pl) 2016-07-19 2019-11-29 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Sposob wytwarzania brekspiprazolu oraz zastosowanie zwiazkow posrednich w sposobie wytwarzania brekspiprazolu
US11123300B2 (en) 2016-08-16 2021-09-21 Hexal Ag Immediate release tablet of a benzothiophene compound
EP3500249A1 (en) 2016-08-16 2019-06-26 Hexal Aktiengesellschaft Pharmaceutical compositions of a benzothiophene compound
CN107936005A (zh) * 2016-10-13 2018-04-20 上海科胜药物研发有限公司 一种依匹哌唑新晶型ii及其制备方法
CN111233848A (zh) * 2016-12-14 2020-06-05 上海博志研新药物技术有限公司 一种依匹哌唑甲醇合物、晶型a、及其制备方法和应用
US11072605B2 (en) 2017-02-02 2021-07-27 Hexal Ag Crystalline brexpiprazole
EP3501506B1 (en) 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
CN111440158A (zh) * 2020-03-24 2020-07-24 石药集团中奇制药技术(石家庄)有限公司 一种盐酸依匹哌唑新晶型及其制备方法
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
WO2023067664A1 (ja) * 2021-10-18 2023-04-27 大塚製薬株式会社 ベンゾチオフェン化合物の新規結晶形及びその製造方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
CN1870980B (zh) 2003-10-23 2010-06-23 大冢制药株式会社 控释无菌阿立哌唑注射剂和方法
WO2006030446A1 (en) 2004-09-13 2006-03-23 Matrix Laboratories Ltd Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
PE20090387A1 (es) * 2007-05-24 2009-04-28 Novartis Ag Formulacion de pasireotida
US20100285476A1 (en) * 2007-10-26 2010-11-11 Rusche James R Methods of identifying histone deacetylase inhibitors useful for neurological disorders
ES2522342T3 (es) * 2008-01-30 2014-11-14 Novartis Ag Formulación de liberación sostenida que comprende octreótido y tres polímeros lineales de polilactida-co-glicolida
TWI589301B (zh) 2010-08-24 2017-07-01 大塚製藥股份有限公司 含有碳苯乙烯基衍生物與聚矽氧油及/或聚矽氧油衍生物之懸浮液以及塊體組成物
JP2012232958A (ja) * 2011-05-09 2012-11-29 Otsuka Pharmaceut Co Ltd 注射製剤
RU2601420C2 (ru) * 2011-07-28 2016-11-10 Оцука Фармасьютикал Ко., Лтд. СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЯ БЕНЗО[b]ТИОФЕНА
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

Also Published As

Publication number Publication date
US20170066752A1 (en) 2017-03-09
IL235044B (en) 2019-05-30
AU2013253372B2 (en) 2016-12-08
PH12014502324B1 (en) 2015-01-12
MX361723B (es) 2018-12-14
WO2013162046A1 (en) 2013-10-31
TWI562991B (en) 2016-12-21
US20210115030A1 (en) 2021-04-22
US9499525B2 (en) 2016-11-22
HUE031997T2 (en) 2017-08-28
FI2841431T4 (fi) 2024-04-18
EA201491933A1 (ru) 2015-03-31
EA026541B1 (ru) 2017-04-28
RS55742B2 (sr) 2024-04-30
KR102160395B1 (ko) 2020-09-28
CN104254530B (zh) 2016-09-21
EP2841431A1 (en) 2015-03-04
EP2841431B2 (en) 2024-01-24
HRP20170242T8 (hr) 2017-09-22
US20230049327A1 (en) 2023-02-16
SMT201700130B (it) 2017-03-08
MX2014012527A (es) 2015-03-19
SG11201406790VA (en) 2014-11-27
RS55742B1 (sr) 2017-07-31
ME02619B (me) 2017-06-20
PH12014502324A1 (en) 2015-01-12
MY170220A (en) 2019-07-10
PL2841431T5 (pl) 2024-07-15
BR112014026424B1 (pt) 2022-09-13
HRP20170242T1 (hr) 2017-04-07
ZA201407477B (en) 2015-12-23
DK2841431T3 (en) 2017-03-06
CN104254530A (zh) 2014-12-31
SI2841431T1 (sl) 2017-03-31
LT2841431T (lt) 2017-03-27
KR20150013189A (ko) 2015-02-04
JP2015514677A (ja) 2015-05-21
US20150087655A1 (en) 2015-03-26
IL235044A0 (en) 2014-12-31
CA2870000A1 (en) 2013-10-31
BR112014026424A2 (pt) 2017-06-27
TW201348229A (zh) 2013-12-01
NZ630260A (en) 2015-09-25
CY1119103T1 (el) 2018-02-14
AR090774A1 (es) 2014-12-03
UA117456C2 (uk) 2018-08-10
US20200140424A1 (en) 2020-05-07
ES2617881T3 (es) 2017-06-20
ES2617881T5 (es) 2024-05-22
IN2014DN08867A (ko) 2015-05-22
US10407415B2 (en) 2019-09-10
EP2841431B1 (en) 2017-01-04
CO7111315A2 (es) 2014-11-10
JP5952917B2 (ja) 2016-07-13
PT2841431T (pt) 2017-03-07
CA2870000C (en) 2021-02-16
AU2013253372A1 (en) 2014-10-30
JO3325B1 (ar) 2019-03-13
HRP20170242T4 (hr) 2024-03-01
DK2841431T4 (da) 2024-02-12
SI2841431T2 (sl) 2024-03-29
PL2841431T3 (pl) 2017-06-30

Similar Documents

Publication Publication Date Title
HK1203073A1 (en) Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
PL3578597T3 (pl) Sposób wytwarzania ekspandowanego granulatu
EP3031052A4 (en) Integral molten salt reactor
EP2812298A4 (en) IMPROVED PROCESS FOR PRODUCING 2,3,3,3-TETRAFLUOROPROPENE
PL2780307T3 (pl) Sposób wytwarzania fluorowodoroolefin
EP2977349A4 (en) METHOD FOR THE PRODUCTION OF A DISULFONYLAMINE ALKALIMETAL SALT
EP2665696A4 (en) PROCESS FOR THE PREPARATION OF 2,3,3,3-TETRAFLUOR-2-PROPENE
ZA201507571B (en) Process for making 2,5-furandicarboxylic acid
EP2814795A4 (en) PROCESS FOR PREPARING HCFC-1233ZD
PL2809635T3 (pl) Sposób wytwarzania 2,3,3,3-tetrafluoropropenu
EP2826766A4 (en) PREPARATION FOR 2,3,3,3-TETRA-FLUOROPROPES
IL240748A0 (en) Methods for generating adenovirus
IL226677A (en) Beta-amyloid production compounds
HK1205097A1 (en) Process for the production of methylbutinol
PL2765149T3 (pl) Sposób wytwarzania katalizatora zawierającego tytan, katalizator zawierający tytan, sposób wytwarzania poliestru i poliester
ZA201501054B (en) Method for producing transition metal compounds, transition metal compounds and use thereof
ZA201401073B (en) Process for preparing atazanavir sulphate
HK1210225A1 (en) Procedure for the production of tiacumicin
PL2964607T3 (pl) Sposób wytwarzania halogeno-n,n-dimetylobenzyloamin
EP2851359A4 (en) PROCESS FOR PRODUCING 4,4 "-DIHIDROXY-M-TERPHENYLS
IL230159A0 (en) Method for the production of 2-amino-5-cyano-n,3-dimethylbenzamide
IL229669A0 (en) Process for the preparation of 1,2,3 triazole 4 carboxamide
PL399603A1 (pl) Sposób wytwarzania 3β,15α-dihydroksy-5α-androst-17-onu
PL400350A1 (pl) Sposób wytwarzania R-(-)-2-chloro-1-(2',4'-dichlorofenylo)-etan-1-olu